Education
About Us
Working with TipRanks
Follow Us
Spyre Therapeutics (SYRE)
NASDAQ:SYRE
Total Valuation
Spyre Therapeutics has a market cap or net worth of $3.41B. The enterprise value is $2.56B.
Market Cap$3.41B
Enterprise Value$2.56B
Share Statistics
Spyre Therapeutics has 78,540,160 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding78,540,160
Owned by Insiders7.48%
Owned by Institutions54.81%
Financial Efficiency
Spyre Therapeutics’s return on equity (ROE) is -0.22 and return on invested capital (ROIC) is -30.53%.
Return on Equity (ROE)-0.22
Return on Assets (ROA)-0.20
Return on Invested Capital (ROIC)-30.53%
Return on Capital Employed (ROCE)-0.31
Revenue Per Employee0.00
Profits Per Employee-2.13M
Employee Count73
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Spyre Therapeutics is ―. Spyre Therapeutics’s PEG ratio is 1.94.
PE Ratio―
PS Ratio0.00
PB Ratio15.85
Price to Fair Value15.85
Price to FCF-66.98
Price to Operating Cash Flow-88.22
PEG Ratio1.94
Income Statement
In the last 12 months, Spyre Therapeutics had revenue of 0.00 and earned -155.20M in profits. Earnings per share was -1.98.
Revenue0.00
Gross Profit-171.65M
Operating Income-209.56M
Pretax Income-155.22M
Net Income-155.20M
EBITDA-209.56M
Earnings Per Share (EPS)-1.98
Cash Flow
In the last 12 months, operating cash flow was -169.25M and capital expenditures 0.00, giving a free cash flow of -169.25M billion.
Operating Cash Flow-169.25M
Free Cash Flow-169.25M
Free Cash Flow per Share-2.15
Dividends & Yields
Spyre Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.74
52-Week Price Change134.89%
50-Day Moving Average33.99
200-Day Moving Average22.67
Relative Strength Index (RSI)75.49
Average Volume (3m)658.34K
Important Dates
Spyre Therapeutics upcoming earnings date is May 7, 2026, TBA (Confirmed).
Last Earnings DateFeb 19, 2026
Next Earnings DateMay 7, 2026
Ex-Dividend Date―
Financial Position
Spyre Therapeutics as a current ratio of 13.25, with Debt / Equity ratio of 0.00%
Current Ratio13.25
Quick Ratio13.25
Debt to Market Cap0.00
Net Debt to EBITDA0.55
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Spyre Therapeutics has paid -15.00K in taxes.
Income Tax-15.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Spyre Therapeutics EV to EBITDA ratio is -72.48, with an EV/FCF ratio of -66.47.
EV to Sales0.00
EV to EBITDA-72.48
EV to Free Cash Flow-66.47
EV to Operating Cash Flow-66.47
Balance Sheet
Spyre Therapeutics has $756.53M in cash and marketable securities with $0.00 in debt, giving a net cash position of $756.53M billion.
Cash & Marketable Securities$756.53M
Total Debt$0.00
Net Cash$756.53M
Net Cash Per Share$9.63
Tangible Book Value Per Share$2.07
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Spyre Therapeutics is $58.71, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$58.71
Price Target Upside36.06% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast―
EPS Growth Forecast-123.65%